OncoMatch/Clinical Trials/NCT05714839
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Is NCT05714839 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Belantamab and Belantamab mafodotin for multiple myeloma.
Treatment: Belantamab · Belantamab mafodotin · Pomalidomide · Dexamethasone — The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). * Part 2: The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of belantamab in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). * Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the belantamab in combination with the pomalidomide-dexamethasone (Pd) standard of care (SoC) backbone. The study will focus on participants with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-myeloma therapy (lenalidomide, pomalidomide, thalidomide)
at least 3 prior lines of anti-myeloma treatments, including any immunomodulatory drug (IMiDs lenalidomide, pomalidomide or thalidomide), a proteasome inhibitor, and an anti-CD38 monoclonal antibodies (mAb) (either in combination or separately)
Must have received: proteasome inhibitor
at least 3 prior lines of anti-myeloma treatments, including any immunomodulatory drug (IMiDs lenalidomide, pomalidomide or thalidomide), a proteasome inhibitor, and an anti-CD38 monoclonal antibodies (mAb) (either in combination or separately)
Must have received: anti-CD38 monoclonal antibody
at least 3 prior lines of anti-myeloma treatments, including any immunomodulatory drug (IMiDs lenalidomide, pomalidomide or thalidomide), a proteasome inhibitor, and an anti-CD38 monoclonal antibodies (mAb) (either in combination or separately)
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cells transplant
Lab requirements
Kidney function
Presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety) [excluded]. Participants with isolated proteinuria resulting from MM are eligible.
Liver function
Has cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal/gastric varices, or persistent jaundice [excluded]
Cardiac function
Evidence of cardiovascular risk including: current clinically significant untreated arrhythmias, QTcF interval >480 msec (Part 1 dose escalation and Part 2 only), history of MI, acute coronary syndromes, coronary angioplasty, stenting or bypass grafting within three months of screening, Class III or IV heart failure (NYHA), uncontrolled hypertension [excluded]
Have adequate organ system function as defined by the laboratory assessments
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- GSK Investigational Site · Bullhead City, Arizona
- GSK Investigational Site · Los Angeles, California
- GSK Investigational Site · Pembroke Pines, Florida
- GSK Investigational Site · Boston, Massachusetts
- GSK Investigational Site · Grand Rapids, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05714839 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages